monensin
concentr
depend
multipl
infect
found
prevent
dna
replic
human
eytomegaloviru
hcmv
well
product
viral
progeni
human
foreskin
fibroblast
drug
affect
dna
replic
herp
simplex
viru
inhibit
consecut
hcmv
dna
synthesi
also
observ
tbltow
delay
addit
drug
within
hour
postinfeet
fulli
revers
upon
remov
viral
replic
proceed
howev
without
impair
cultur
treat
monensin
prior
infect
induct
viral
dna
polymeras
activ
imped
inhibitor
analysi
proteinand
glyeoprotein
synthesi
reveal
monensin
interf
product
number
hcmvspeeifi
polypeptid
furthermor
evid
obtain
drug
may
hinder
intraeellular
transport
kd
glyeopolypeptid
ionophor
monensin
antibiot
streptomyc
cinnamonensi
found
wide
applic
recent
studi
biosynthesi
viral
glyeoprotein
although
evid
multipl
site
action
compound
appar
interfer
like
eg
tunieamyein
primari
step
glyeosyl
glyeoprotein
transport
within
golgi
apparatu
thu
later
stage
process
envelop
virus
mode
action
implic
signific
reduct
releas
progeni
us
infect
cell
addit
assembl
may
affect
virus
bud
outer
plasma
membran
regard
herpesvirus
receiv
envelop
nuclear
inner
cytoplasm
membran
author
agre
monensin
mainli
affect
viral
egress
wherea
viral
morphogenesi
hardli
impair
furthermor
express
presenc
monensin
herp
simplex
virusinduc
surfac
membran
antigen
target
immunolysi
either
reduc
abolish
appear
unimpair
bovin
herp
virusinfect
cell
compar
member
human
herpesviru
group
human
c
comegaloviru
hcmv
present
sever
characterist
properti
eg
pronounc
speci
specif
long
replic
cycl
particular
depend
host
cell
function
yet
anoth
properti
distinguish
hcmv
host
cell
system
sensit
virusinduc
dna
replic
inhibitor
glycosyl
tunicamycin
ineffect
hand
dna
replic
herp
simplex
viru
hsv
infect
cell
evid
forward
context
tbr
hcmv
system
earli
virusinduc
chromatinassoci
glycoprotein
target
inhibitor
investig
initi
observ
verifi
extend
use
monensin
found
also
prevent
hcmv
dna
replic
furthermor
experi
suggest
drug
may
affect
intracellular
transport
viresinduc
glycoprotein
human
foreskin
fibroblast
hff
gener
donat
dr
b
fleckenstein
erlangen
feder
republ
germani
use
passag
experi
well
viru
propag
monolay
cultiv
plastic
flask
variou
size
nunc
wiesbaden
feder
republ
germani
cm
correspond
cell
eagl
minimum
essenti
medium
earl
salt
solut
mem
gibco
eggenstein
feder
republ
germani
supplement
unit
penicillin
plu
g
gentamycinml
nd
per
cent
fetal
calf
serum
fc
experi
perform
cultur
prtialli
altest
serum
depriv
per
cent
fc
hour
begin
averag
day
cultur
rech
confluenc
town
strain
hcmv
propag
confluent
hff
multipl
infect
moi
use
per
cent
fc
ko
strain
herp
simplex
viru
type
propag
cell
serumfre
medium
viru
stock
hcmv
prepar
describ
previous
purif
hcmv
collect
cellfre
cultur
medium
subject
centrifug
gradient
per
cent
sucros
experiment
infect
hff
perform
stock
viru
desir
mot
indic
result
condit
use
per
cent
hcmvor
hsvinfect
cell
respect
contain
viral
antigen
viru
titer
determin
endpoint
dilut
method
combin
indirect
immunofluoresc
viral
antigen
puls
label
dna
spact
cimmol
use
gciml
cultur
medium
protein
glyeoprotein
label
perform
spact
cimmol
shmannos
spaet
cimmol
spact
cimmol
use
ci
ciml
cultur
medium
either
deplet
methionin
case
tritiat
sugar
glucos
replac
sodium
pyruv
label
glyeoprotein
purifi
hcmv
vitro
hborohydrid
spact
cimmol
carri
describ
lutjokon
et
al
radiochem
purchas
amersham
buehler
frankfurt
feder
republ
germani
dna
extract
label
cell
follow
lysi
per
cent
sodium
dodecyl
sulphat
sd
phenolchloroformisoamyl
alcohol
treatment
dna
content
sampl
estim
method
gile
myeg
separ
viral
host
cell
dna
achiev
isopycn
centrifug
neutrm
mean
densiti
gml
hff
dna
band
densiti
gml
hcmv
dna
gml
dna
gml
determin
dna
polymeras
activ
hff
cell
subject
desir
treatment
wash
twice
cold
phosphat
buffer
salin
pb
harvest
pb
scrape
hour
pi
prior
solubil
ml
tnt
buffer
mm
ph
per
cent
triton
sonic
maximum
set
second
branson
sonifi
follow
sediment
insolubl
materi
g
supernat
cellular
extract
examin
dna
polymeras
activ
basic
assay
contain
g
bovin
serum
albumin
bsa
mm
ph
dithiothreitol
dtr
g
activ
calf
thymu
dna
mm
datp
dctp
dgtp
label
substrat
spact
ctminpmol
cellular
extract
correspond
gg
protein
andor
inhibitor
supplement
concentr
indic
tesult
incub
perform
duplic
assay
minut
c
prior
determin
acid
insolubl
radioact
see
sdspage
separ
polypeptid
perform
accord
lxmli
describ
gallwltz
et
al
use
either
total
cellular
cytoplasm
nuclear
extract
prepar
extract
hff
v
cell
wash
twice
cold
pb
harvest
scrape
pb
solubil
ml
supplement
per
cent
sodium
deoxyehol
doc
total
extract
obtain
subsequ
sonic
sediment
insolubl
materi
see
prepar
subcellular
extract
sediment
nuclei
follow
directli
treatment
tntdoc
buffer
prior
addit
wash
ml
buffer
combin
supernat
pool
repres
cytoplasm
extract
nuclear
pellet
resuspend
ml
tntdoc
buffer
subject
sonif
follow
sediment
insolubl
materi
supernat
use
nuclear
extract
eleetrophoresi
slab
gel
subject
fixat
stain
fluorographi
accord
procedur
boer
laskey
use
rotifluoreszint
roth
karlsrub
feder
republ
germani
impregn
latter
step
omit
analysi
includ
immunoblot
immunobtot
immunoblot
electrotransf
polypeptid
slab
gel
sdspage
nitrocellulos
sheet
ba
schleicher
schiill
dussel
feder
republ
germani
perform
v
chamber
construct
laboratori
transfer
buffer
consist
mm
trishcl
ph
glycin
per
cent
methanol
indirect
immunostain
carri
dilut
antihcmv
hyperimmun
serum
biotest
pharlna
dreieieh
feder
republ
germani
human
recoltvatesc
sera
test
presenc
ofhcmvspecif
igg
standard
enzymelink
immunosorb
assay
elisa
first
antibodi
horseradish
peroxidaseconjug
rabbit
antihuman
igg
dakopatt
hamburg
feder
republ
germani
second
antibodi
dilut
use
substrat
triehloroaceti
acid
tca
precipit
radioact
label
maeromolecul
determin
transfer
aliquot
glass
fiber
filter
gfc
schteieher
schtill
dassel
feder
republ
germani
success
wash
per
cent
tca
ethanol
ether
follow
count
toluenebas
scintil
cocktail
quickszint
roth
karlsruh
feder
republ
germani
protein
content
cellular
extract
estim
method
lowli
et
al
phosphonoacet
acid
paa
monensin
purchas
sigma
deisenhofen
feder
republ
germani
tunieamycin
calbiochem
la
jolla
usa
typicm
experi
determin
infect
cell
dna
synthesi
presenc
monensin
parallel
cultur
hff
cell
infect
hcmv
moi
puls
label
attthymidin
ciml
late
phase
consecut
infecti
cycl
prior
infect
hff
subject
serum
starvat
avoid
cellular
stimul
addit
hcmv
condit
concentr
effect
abolish
virusmedi
induct
precursor
incorpor
tabl
exp
higher
moi
use
drug
concentr
rais
tabl
exp
obtain
compar
suppress
uptak
subsequ
experi
moi
chosen
contrast
herp
simplex
viru
hsv
induc
dna
synthesi
prove
resist
monensin
even
rel
high
concentr
also
prevent
hcmvmediat
induct
ahthymidin
ineorpor
fail
inhibit
trigger
hsv
serummedi
induct
preeursor
uptak
hand
sensit
action
monensin
tabl
exp
wherea
arrest
hff
inhibit
shown
subsequ
analysi
infeet
eell
dna
isopyeni
eentrifug
neutral
reveal
inhibit
homvhost
cell
system
presenc
monensin
inde
due
prevent
thymidin
incorpor
viral
dna
fig
b
label
hsv
dna
hand
affect
drug
fig
c
expect
observ
drug
also
prevent
product
intraa
well
extraeellular
hcmv
progeni
shown
examin
whether
pretreat
cell
support
viral
replic
confluent
serumstarv
hff
expos
variou
concentr
monensin
prior
viru
infect
subsequ
puls
label
interv
expect
viral
dna
synthesi
fig
pretreat
drug
concentr
inhibitori
effect
conseeut
precursor
uptak
condit
likewis
anmysi
dna
show
synthesi
viral
dna
essenti
unimpair
compar
control
fig
wo
monpr
pretreat
higher
drug
concentr
eg
tx
induc
sign
begin
eytotoxi
led
reduc
incorpor
viral
dna
shown
experiment
setup
cultur
infect
subsequ
kept
presenc
monensin
tim
hour
time
drug
remov
cultur
refe
fresh
medium
without
inhibitor
subject
three
sequenti
puls
tritiat
thymidin
hour
interv
monitor
dna
synthesi
fig
b
protocol
prevent
subsequ
recoveri
viral
dna
replic
within
hour
remov
observ
base
compar
anmysi
isopycni
centrifug
dna
sampl
untreat
drugtreat
infect
cultur
label
correspond
puls
interv
fig
b
wo
monint
follow
experi
serv
determin
differ
sensit
hcmvinduc
dna
synthesi
drug
infecti
cycl
purpos
serumstarv
hff
infect
describ
drug
addit
tzm
howev
follow
delay
pi
prior
puls
label
hour
pi
fig
dna
extract
hcmvinfeet
hff
left
untreat
wo
expos
monensin
monpr
txm
prior
infect
puls
label
txci
hour
pi
b
hcmvinfeet
hff
left
untreat
wo
expos
monensin
monint
txm
hour
pi
puls
label
tritiat
thymidin
txcimi
hour
wo
hour
pi
monint
untreat
infect
parallel
cultur
label
interv
control
pig
wo
experimentm
approach
show
drug
addit
hour
pi
effect
complet
abolish
conseeut
viral
dna
synthesi
fig
ad
hour
pi
monensin
reduc
fig
b
e
drug
addit
later
time
impair
precursor
incorpor
viral
dna
fig
e
exclud
obviou
possibl
suppress
monensin
induct
viral
dna
polymeras
cell
extract
prepar
drugtreat
infect
hff
hour
pi
activ
compar
appropri
control
extract
tabl
condit
use
monensin
imped
induct
enzym
activ
show
characterist
properti
regard
vitro
paasensit
salt
stimul
addit
drug
inhibit
dna
polymeras
activ
vitro
assay
tabl
observ
suppress
ofhcmv
dna
synthesi
one
also
expect
impair
presenc
monensin
express
late
al
pol
teptid
prove
conjectur
parallel
cultur
cell
infect
hff
subject
drug
treatment
puls
label
fig
tritiat
sugar
fig
hour
pi
concentr
use
monensin
prevent
virusmedi
increas
precursor
uptak
ie
specif
radioact
protein
sampl
drugtreat
infect
cell
equal
uninfect
cell
case
extract
approxim
cpm
protein
decreas
per
cent
respect
control
cell
follow
label
tritiat
sugar
epm
protein
ahmannoseand
extract
respect
analysi
sdspage
fluorographi
reveal
methioninelabel
extract
monensin
inhibit
synthesi
promin
polypeptid
fig
lane
b
e
kilodalton
kd
assum
repres
known
major
viral
protein
compar
cultur
expos
paa
fig
lane
e
monensin
treatment
also
prevent
label
polypeptid
kd
fig
lane
e
e
observ
essentimli
verifi
n
e
x
e
n
e
immunoblot
p
l
e
h
u
n
hcmvspecif
r
e
e
n
v
l
e
e
e
n
sera
fig
b
latter
techniqu
show
addit
suppress
b
drug
two
polyi
eptid
r
n
g
e
kd
n
two
kd
respect
fig
b
lane
e
three
viral
polypeptid
recogn
molecular
weight
r
n
g
e
p
p
r
x
e
l
kd
n
kd
fig
analysi
extract
label
tritiat
sugar
fig
show
h
n
e
n
n
interf
glueosaminebut
n
n
e
incorpor
k
p
r
u
c
fig
n
b
lane
b
u
p
k
e
larg
reduc
hand
p
r
e
c
u
r
r
kd
glyeopolypeptid
fig
b
lane
b
interestingli
n
glyeop
r
e
n
label
purifi
viru
p
r
e
p
r
n
g
r
e
fig
c
lane
c
furthermor
drug
treatment
abohsh
precursor
uptak
kd
glycoprotein
result
induct
glycosyl
polypeptid
kd
fig
b
lane
tunicamycinresist
incorpor
obviou
high
molecular
weight
rang
labelhng
ahglucosamin
fig
b
lane
e
observ
sensit
hcmv
dna
synthesi
delay
addit
monensin
restrict
initi
phase
infecti
cycl
support
specul
intracellutar
transport
glycopotypeptid
may
involv
thu
attempt
prove
assumpt
follow
experiment
approach
hcmvinfect
hff
label
tritiat
sugar
hour
pi
fig
lane
c
subsequ
subject
chase
presenc
monensin
hour
pi
prior
cell
fraction
fig
lane
uninfect
well
infect
cultur
chase
without
inhibitor
includ
control
fig
lane
b
analysi
cytoplasm
nuclear
extract
sdspage
fluorographi
fig
show
cytoplasm
extract
hcmvinfect
cell
chase
presenc
drug
retain
glycopolypeptid
rang
kd
fig
lane
e
cy
appar
chase
nuclear
fraction
absenc
inhibitor
fig
lane
nu
immunoblot
fig
b
hcmatspecif
antisera
extract
chase
cultur
reveal
decreas
amount
presenc
monensin
viral
polypeptid
kd
see
support
assumpt
parallel
tluorogram
fig
monensin
affect
intracehular
transport
kd
virusspecif
product
use
inhibitor
analysi
complex
biolog
system
often
hamper
advers
side
effect
possibl
consid
allthemor
result
obtain
featur
immedi
consequ
known
mechan
inhibitor
action
case
drug
use
sever
observ
argu
toxic
concentr
use
eg
hrevers
damag
cellular
polypeptid
synthesi
neither
treatment
cultur
prior
infect
intermediari
exposur
infect
cell
addit
monensin
infecti
cycl
prevent
resumpt
progress
consecut
hcmv
dna
synthesi
addit
monensin
show
inhibitori
effect
viral
dna
synthesi
hsvinfect
hff
ii
analysi
irrfiuenc
monensin
viral
polypeptid
synthesi
determin
precursor
incorpor
immunblot
favor
rel
select
ettect
particularli
obviou
protocol
delay
drug
addit
use
eg
fig
b
furthermor
monensin
effeet
specif
consist
chang
glycoprotein
synthesi
infect
cell
inde
reflect
action
posttransl
protein
modif
eg
rel
resist
incorpor
compar
main
virusinduc
glyeoprotein
gp
lahetl
ie
gp
monensin
altow
incorpor
gp
wherea
label
gp
abolish
new
strongiy
label
polypeptid
kd
induc
minor
band
lower
molecular
weight
appear
sugar
label
consid
incorpor
addit
gp
reveal
rang
kd
monensin
prevent
appear
radioact
band
high
molecular
weight
posit
kd
well
kd
posit
allow
uptak
glycopolypeptid
kd
view
pereira
elabor
analysi
polymorph
hcmvspeeific
glycoprotein
perform
also
use
reduc
condit
electrophoret
analysi
gp
whose
synthesi
appear
unimpair
presenc
monensin
may
repres
partial
process
immatur
form
gpa
gpb
respect
recent
repot
rasvss
et
al
btt
auger
support
view
matur
gpa
complex
involv
cleavag
complex
precursor
monensin
may
experiment
aid
defin
influenc
posttransl
protein
modif
fmal
gpa
process
observ
fig
suggest
major
gp
kd
made
earli
infect
absenc
viral
dna
synthesi
relationship
main
viral
envelop
gp
migrat
slightli
faster
condit
remain
determin
taken
togeth
interfer
monensin
hcmvinduc
glycopolypeptidea
well
polypeptid
synthesi
fig
appear
much
pronounc
describ
hsvinfect
cultur
particular
inhibitori
effect
monensin
viral
dna
synthesi
distinguish
hcmv
hsv
underli
mechan
difficult
assess
previou
observ
prevent
hcmv
dna
synthesi
glycosyl
inhibitor
well
find
describ
suggest
glyeosyl
product
particip
control
viral
dna
synthesi
observ
monensin
imped
synthesi
sever
virusspecif
polypeptid
includ
structur
protein
may
thu
reflect
secondari
effect
drug
appear
pertin
context
defin
specif
hostor
virusspecif
kd
gp
whose
intraeellular
distribut
affect
monensin
analysi
glyeoprotein
process
serumstimul
hff
whose
dna
synthesi
equal
sensit
action
monensin
hope
shed
light
question
